These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1161 related items for PubMed ID: 17140455

  • 1. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma.
    Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir IR, Lu L, Irvin D, Black KL, Yu JS.
    Mol Cancer; 2006 Dec 02; 5():67. PubMed ID: 17140455
    [Abstract] [Full Text] [Related]

  • 2. Influence of Etoposide on anti-apoptotic and multidrug resistance-associated protein genes in CD133 positive U251 glioblastoma stem-like cells.
    Jin F, Zhao L, Guo YJ, Zhao WJ, Zhang H, Wang HT, Shao T, Zhang SL, Wei YJ, Feng J, Jiang XB, Zhao HY.
    Brain Res; 2010 Jun 08; 1336():103-11. PubMed ID: 20388502
    [Abstract] [Full Text] [Related]

  • 3. Enhanced MDR1 expression and chemoresistance of cancer stem cells derived from glioblastoma.
    Nakai E, Park K, Yawata T, Chihara T, Kumazawa A, Nakabayashi H, Shimizu K.
    Cancer Invest; 2009 Nov 08; 27(9):901-8. PubMed ID: 19832037
    [Abstract] [Full Text] [Related]

  • 4. Expression of multidrug resistance genes in normal and cancer stem cells.
    Shervington A, Lu C.
    Cancer Invest; 2008 Jun 08; 26(5):535-42. PubMed ID: 18568776
    [Abstract] [Full Text] [Related]

  • 5. Glioblastoma stem cells resistant to temozolomide-induced autophagy.
    Fu J, Liu ZG, Liu XM, Chen FR, Shi HL, Pangjesse CS, Ng HK, Chen ZP.
    Chin Med J (Engl); 2009 Jun 05; 122(11):1255-9. PubMed ID: 19567133
    [Abstract] [Full Text] [Related]

  • 6. Heterogeneous phenotype of human glioblastoma: in vitro study.
    Denysenko T, Gennero L, Juenemann C, Morra I, Masperi P, Ceroni V, Pragliola A, Ponzetto A, Melcarne A.
    Cell Biochem Funct; 2014 Mar 05; 32(2):164-76. PubMed ID: 23836332
    [Abstract] [Full Text] [Related]

  • 7. Coexpression analysis of CD133 and CD44 identifies proneural and mesenchymal subtypes of glioblastoma multiforme.
    Brown DV, Daniel PM, D'Abaco GM, Gogos A, Ng W, Morokoff AP, Mantamadiotis T.
    Oncotarget; 2015 Mar 20; 6(8):6267-80. PubMed ID: 25749043
    [Abstract] [Full Text] [Related]

  • 8. p53 upregulated modulator of apoptosis sensitizes drug-resistant U251 glioblastoma stem cells to temozolomide through enhanced apoptosis.
    Miao W, Liu X, Wang H, Fan Y, Lian S, Yang X, Wang X, Guo G, Li Q, Wang S.
    Mol Med Rep; 2015 Jun 20; 11(6):4165-73. PubMed ID: 25625235
    [Abstract] [Full Text] [Related]

  • 9. Prognostic impact of CD133 mRNA expression in 48 glioblastoma patients treated with concomitant radiochemotherapy: a prospective patient cohort at a single institution.
    Metellus P, Nanni-Metellus I, Delfino C, Colin C, Tchogandjian A, Coulibaly B, Fina F, Loundou A, Barrie M, Chinot O, Ouafik L, Figarella-Branger D.
    Ann Surg Oncol; 2011 Oct 20; 18(10):2937-45. PubMed ID: 21479688
    [Abstract] [Full Text] [Related]

  • 10. Molecular properties of CD133+ glioblastoma stem cells derived from treatment-refractory recurrent brain tumors.
    Liu Q, Nguyen DH, Dong Q, Shitaku P, Chung K, Liu OY, Tso JL, Liu JY, Konkankit V, Cloughesy TF, Mischel PS, Lane TF, Liau LM, Nelson SF, Tso CL.
    J Neurooncol; 2009 Aug 20; 94(1):1-19. PubMed ID: 19468690
    [Abstract] [Full Text] [Related]

  • 11. Arsenic oxide targets stem cell marker CD133/prominin-1 in gallbladder carcinoma.
    Ai Z, Pan H, Suo T, Lv C, Wang Y, Tong S, Liu H.
    Cancer Lett; 2011 Nov 28; 310(2):181-7. PubMed ID: 21788103
    [Abstract] [Full Text] [Related]

  • 12. Temozolomide preferentially depletes cancer stem cells in glioblastoma.
    Beier D, Röhrl S, Pillai DR, Schwarz S, Kunz-Schughart LA, Leukel P, Proescholdt M, Brawanski A, Bogdahn U, Trampe-Kieslich A, Giebel B, Wischhusen J, Reifenberger G, Hau P, Beier CP.
    Cancer Res; 2008 Jul 15; 68(14):5706-15. PubMed ID: 18632623
    [Abstract] [Full Text] [Related]

  • 13. CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles.
    Beier D, Hau P, Proescholdt M, Lohmeier A, Wischhusen J, Oefner PJ, Aigner L, Brawanski A, Bogdahn U, Beier CP.
    Cancer Res; 2007 May 01; 67(9):4010-5. PubMed ID: 17483311
    [Abstract] [Full Text] [Related]

  • 14. Expression of CD133 and other putative stem cell markers in uveal melanoma.
    Thill M, Berna MJ, Grierson R, Reinhart I, Voelkel T, Piechaczek C, Galambos P, Jager MJ, Richard G, Lange C, Gehling UM.
    Melanoma Res; 2011 Oct 01; 21(5):405-16. PubMed ID: 21900792
    [Abstract] [Full Text] [Related]

  • 15. Pyrvinium Targets CD133 in Human Glioblastoma Brain Tumor-Initiating Cells.
    Venugopal C, Hallett R, Vora P, Manoranjan B, Mahendram S, Qazi MA, McFarlane N, Subapanditha M, Nolte SM, Singh M, Bakhshinyan D, Garg N, Vijayakumar T, Lach B, Provias JP, Reddy K, Murty NK, Doble BW, Bhatia M, Hassell JA, Singh SK.
    Clin Cancer Res; 2015 Dec 01; 21(23):5324-37. PubMed ID: 26152745
    [Abstract] [Full Text] [Related]

  • 16. Transcriptional profiles of CD133+ and CD133- glioblastoma-derived cancer stem cell lines suggest different cells of origin.
    Lottaz C, Beier D, Meyer K, Kumar P, Hermann A, Schwarz J, Junker M, Oefner PJ, Bogdahn U, Wischhusen J, Spang R, Storch A, Beier CP.
    Cancer Res; 2010 Mar 01; 70(5):2030-40. PubMed ID: 20145155
    [Abstract] [Full Text] [Related]

  • 17. Identification of novel human leukocyte antigen-A*0201-restricted, cytotoxic T lymphocyte epitopes on CD133 for cancer stem cell immunotherapy.
    Ji J, Judkowski VA, Liu G, Wang H, Bunying A, Li Z, Xu M, Bender J, Pinilla C, Yu JS.
    Stem Cells Transl Med; 2014 Mar 01; 3(3):356-64. PubMed ID: 24375541
    [Abstract] [Full Text] [Related]

  • 18. Expansion of CD133-positive glioma cells in recurrent de novo glioblastomas after radiotherapy and chemotherapy.
    Tamura K, Aoyagi M, Ando N, Ogishima T, Wakimoto H, Yamamoto M, Ohno K.
    J Neurosurg; 2013 Nov 01; 119(5):1145-55. PubMed ID: 23991844
    [Abstract] [Full Text] [Related]

  • 19. Sox2, a stemness gene, regulates tumor-initiating and drug-resistant properties in CD133-positive glioblastoma stem cells.
    Song WS, Yang YP, Huang CS, Lu KH, Liu WH, Wu WW, Lee YY, Lo WL, Lee SD, Chen YW, Huang PI, Chen MT.
    J Chin Med Assoc; 2016 Oct 01; 79(10):538-45. PubMed ID: 27530866
    [Abstract] [Full Text] [Related]

  • 20. NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts.
    Fan X, Khaki L, Zhu TS, Soules ME, Talsma CE, Gul N, Koh C, Zhang J, Li YM, Maciaczyk J, Nikkhah G, Dimeco F, Piccirillo S, Vescovi AL, Eberhart CG.
    Stem Cells; 2010 Jan 01; 28(1):5-16. PubMed ID: 19904829
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 59.